C02CA04 - Doxazosin |
Propably not porphyrinogenic |
PNP |
Rationale
No data pointing to CYP-interaction. Clinical experience of non-porphyrinogenicity.
Chemical description
Quinazoline derivative
Therapeutic characteristics
Antihypertensive quinazoline derivative, also used in prostatic hyperplasia. Dose 4-8 mg/d.
Metabolism and pharmakokinetics
Extensively metabolised in the liver, primarily excreted in faeces as metabolites and only a small amount of unchanged drug. Oxidative metabolism occurs, but data on CYP450 metabolism are lacking.
Personal communication
Thunell, patient reports (n=5): tolerated. Andersson, patient reports(n=11): tolerated.
Published experience
Doxazosin was used uneventfully in 60 year old AIP woman (Gorchein, 1997). Also used uneventfully in AIP man of 55 (Turton-Weeks, 2001).
IPNet drug reports
Uneventful use reported in 19 patients with acute porphyria.
References
- Scientific articles
- Gorchein A. Drug treatment of hypertension in acute intermittent porphyria: Doxazosin and amlodipine. British Journal of Clinical Pharmacology 1997; 43(3):339-340. PMID 9088595. #1238
- Turton-Weeks S, Barone GW, et al. Pretransplant evaluation of a patient with acute intermittent porphyria. Progress in Transplantation 2001; 11(3):214-216. PMID 11949465. #4392
Similar drugs
© NAPOS 2024